Stock ZTS ZOETIS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zoetis Inc.

Equities

ZTS

US98978V1035

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
158.4 USD +3.30% Intraday chart for Zoetis Inc. +8.14% -19.73%
Apr. 23 Barclays Adjusts Zoetis' Price Target to $230 From $260, Keeps Overweight Rating MT
Apr. 22 Jefferies Lowers Zoetis Price Target to $200 from $220 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 63,038 78,657 115,457 68,303 90,615 72,390 - -
Enterprise Value (EV) 1 67,551 82,252 118,564 72,626 95,138 76,699 76,193 75,769
P/E ratio 42.6 x 48.4 x 57.1 x 32.6 x 38.9 x 29 x 26.1 x 23.9 x
Yield 0.52% 0.51% 0.44% 0.92% 0.79% 1.07% 1.22% 1.36%
Capitalization / Revenue 10.1 x 11.8 x 14.8 x 8.45 x 10.6 x 7.9 x 7.38 x 6.92 x
EV / Revenue 10.8 x 12.3 x 15.2 x 8.99 x 11.1 x 8.37 x 7.77 x 7.25 x
EV / EBITDA 24.6 x 28 x 34.5 x 20.4 x 25.6 x 19.1 x 17.4 x 16.4 x
EV / FCF 50.6 x 49.2 x 68.3 x 54.8 x 58.7 x 36.4 x 31.4 x 28.2 x
FCF Yield 1.98% 2.03% 1.46% 1.83% 1.7% 2.75% 3.18% 3.55%
Price to Book 23.2 x 20.9 x 25.4 x 15.4 x 18.1 x 12.3 x 10.5 x 8.8 x
Nbr of stocks (in thousands) 476,299 475,268 473,126 466,072 459,114 456,947 - -
Reference price 2 132.4 165.5 244.0 146.6 197.4 158.4 158.4 158.4
Announcement Date 2/13/20 2/16/21 2/15/22 2/14/23 2/13/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 6,260 6,675 7,776 8,080 8,544 9,166 9,812 10,456
EBITDA 1 2,743 2,940 3,434 3,561 3,722 4,009 4,367 4,631
EBIT 1 2,331 2,499 2,986 3,096 3,231 3,523 3,857 4,173
Operating Margin 37.24% 37.44% 38.4% 38.32% 37.82% 38.44% 39.31% 39.91%
Earnings before Tax (EBT) 1 1,801 1,996 2,488 2,656 2,936 3,228 3,499 3,769
Net income 1 1,500 1,638 2,037 2,114 2,344 2,533 2,775 3,009
Net margin 23.96% 24.54% 26.2% 26.16% 27.43% 27.63% 28.28% 28.78%
EPS 2 3.110 3.420 4.270 4.490 5.070 5.472 6.076 6.630
Free Cash Flow 1 1,335 1,673 1,736 1,326 1,621 2,109 2,423 2,690
FCF margin 21.33% 25.06% 22.33% 16.41% 18.97% 23.01% 24.7% 25.73%
FCF Conversion (EBITDA) 48.67% 56.9% 50.55% 37.24% 43.55% 52.61% 55.49% 58.1%
FCF Conversion (Net income) 89% 102.14% 85.22% 62.72% 69.16% 83.27% 87.32% 89.4%
Dividend per Share 2 0.6920 0.8500 1.075 1.350 1.557 1.701 1.930 2.161
Announcement Date 2/13/20 2/16/21 2/15/22 2/14/23 2/13/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 1,990 1,967 1,986 2,052 2,002 2,040 2,000 2,180 2,151 2,213 2,155 2,327 2,312 2,365 2,278
EBITDA 1 839 756 946 887 879 849 857 - - - 898 977 970 962 -
EBIT 1 774 639 832 770 764 730 770 877 839 745 833.9 927.1 916 864.7 895
Operating Margin 38.89% 32.49% 41.89% 37.52% 38.16% 35.78% 38.5% 40.23% 39.01% 33.66% 38.69% 39.84% 39.62% 36.57% 39.3%
Earnings before Tax (EBT) 1 659 - - - - - - - - 650 768 849 846 840 -
Net income 1 552 414 595 529 529 461 552 671 596 525 591.3 689.2 656.9 633.7 -
Net margin 27.74% 21.05% 29.96% 25.78% 26.42% 22.6% 27.6% 30.78% 27.71% 23.72% 27.44% 29.61% 28.41% 26.8% -
EPS 2 1.160 0.8700 1.260 1.120 1.130 0.9900 1.190 1.450 1.290 1.140 1.275 1.450 1.420 1.342 1.335
Dividend per Share 2 0.2500 0.3250 0.3250 0.3250 0.3250 0.3250 0.3750 0.3750 - 0.8070 0.4150 0.4150 0.4150 0.4150 0.4600
Announcement Date 11/4/21 2/15/22 5/5/22 8/4/22 11/3/22 2/14/23 5/4/23 8/8/23 11/2/23 2/13/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 4,513 3,595 3,107 4,323 4,523 4,309 3,803 3,380
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.645 x 1.223 x 0.9048 x 1.214 x 1.215 x 1.075 x 0.8709 x 0.7298 x
Free Cash Flow 1 1,335 1,673 1,736 1,326 1,621 2,109 2,423 2,690
ROE (net income / shareholders' equity) 71.7% 56.9% 49% 47.3% 52.3% 47.9% 45.6% 43.2%
ROA (Net income/ Total Assets) 15.7% 14.7% 14.8% 14.7% 16% 17% 17.1% 17.2%
Assets 1 9,539 11,172 13,754 14,413 14,606 14,904 16,206 17,464
Book Value Per Share 2 5.690 7.930 9.610 9.490 10.90 12.90 15.10 18.00
Cash Flow per Share 2 3.730 4.440 4.640 4.060 5.090 6.280 7.060 7.860
Capex 1 460 453 477 586 732 858 874 834
Capex / Sales 7.35% 6.79% 6.13% 7.25% 8.57% 9.36% 8.91% 7.98%
Announcement Date 2/13/20 2/16/21 2/15/22 2/14/23 2/13/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Zoetis Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
158.4 USD
Average target price
215.2 USD
Spread / Average Target
+35.83%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Veterinary Drugs

1st Jan change Capi.
ZOETIS INC. Stock Zoetis Inc.
-19.73% 72.39B
ELANCO ANIMAL HEALTH INCORPORATED Stock Elanco Animal Health Incorporated
-11.01% 6.54B
BLUESTAR ADISSEO COMPANY Stock Bluestar Adisseo Company
+15.88% 3.43B
VIRBAC Stock Virbac
-2.92% 3.12B
VIMIAN GROUP AB Stock Vimian Group AB
-0.68% 1.4B
JINYU BIO-TECHNOLOGY CO., LTD. Stock Jinyu Bio-technology Co., Ltd.
-17.27% 1.34B
VETOQUINOL SA Stock Vetoquinol SA
-2.73% 1.26B
WUHAN KEQIAN BIOLOGY CO.,LTD Stock Wuhan Keqian Biology Co.,Ltd
-14.67% 1.12B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD. Stock Tianjin Ringpu Bio-Technology Co.,Ltd.
-5.37% 990M
PULIKE BIOLOGICAL ENGINEERING, INC. Stock Pulike Biological Engineering, Inc.
-24.06% 805M
Veterinary Drugs
  1. Stock Market
  2. Equities
  3. ZTS Stock
  4. Financials Zoetis Inc.